Samhsa - mat collier 2021 - collier county medication assisted treatment services population of focus for collier county medication assisted treatment services (collier mat) shall be persons with an…

Samhsa - mat collier 2021 - collier county medication assisted treatment services population of focus for collier county medication assisted treatment services (collier mat) shall be persons with an opioid use disorder (OUD) seeking or receiving mat. The desired outcomes are an increase in the number of collier county residents with OUD receiving mat and a decrease in illicit opioid drug use and prescription opioid misuse at six-month follow-up. 380 unduplicated clients will be served. Collier mat will increase mat access among rural collier county residents as well as jail inmates with a history of OUD who will be released from custody in four months or less. Program goals and objectives include: goal 1: increase the number of individuals receiving mat services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders. Objective 1.1: establish the baseline number of collier county residents receiving mat pharmacotherapeutic services from DLC during 2020. Objective 1.2: increase the number of collier county residents receiving mat pharmacotherapeutic services annually by at least 10% above baseline in year 1 and 25% above baseline in years 2-5. Goal 2: increase the number of individuals receiving integrated care. Objective 2.1: establish the baseline number of collier county residents receiving integrated care - pharmacotherapy in tandem with either therapy, peer recovery support and/or case management services - during 2020. Objective 2.2: increase the number of collier county residents receiving integrated care annually by at least 10% above baseline during year 1 and 25% above baseline in years 2-5. Goal 3: decrease illicit drug use at 6-month and post treatment follow-UPS compared to pre-treatment. Objective 3.1: establish baseline using data from year 1 participants. Objective 3.2: decrease by at least 5% from baseline in years 2-5. Goal 4: decrease the use of prescription opioids in a non-prescribed manner at 6-month and post treatment follow-UPS, compared to pre-treatment frequency of use. Objective 4.1: establish baseline using data from year 1 participants. Objective 4.2: decrease by at least 5% from baseline in years 2-5. Collier mat will utilize only FDA-approved medications for the maintenance treatment of opioid use disorder. Medications include naloxone, buprenorphine products including sublingual tablets or film, buccal film, and extended release, long-acting injectable buprenorphine formulations; and injectable naltrexone. A plan will be implemented to mitigate diversion risk of buprenorphine. Mat will be provided in combination with comprehensive OUD psychosocial services, including counseling, behavioral therapies, recovery support services, and other clinically indicated services provided by collier mat and community partners. Collier mat will report performance on the number of clients served, diagnosis, specific medications prescribed and duration of treatment with those medications, abstinence from illicit drug use and alcohol misuse, housing and employment status, criminal justice system involvement, and access to and engagement with services